SCHEMBL6164858

SCHEMBL6164858

CC(C)Oc1ccc(CNC(=O)c2c[nH]c3c(c2=O)CCCC3)c(F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
KCNK3 O14649 1/20 0.36
KCNK5 O95279 1/20 0.36
KCNA5 P22460 1/20 0.36
KCNK17 Q96T54 1/20 0.36
KCNK9 Q9NPC2 1/20 0.36
ADORA2A P29274 2/20 0.36
ADORA1 P30542 2/20 0.36
NR1H4 Q96RI1 2/20 0.35
EPHX2 P34913 1/20 0.35
POLB P06746 1/20 0.35
EZH2 Q15910 1/20 0.35
TP53 P04637 1/20 0.35
THRB P10828 1/20 0.35
MAPT P10636 1/20 0.35
PARP1 P09874 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6162486 0.98 PDE4A (0.39) PDE4APDE4BPDE4CPDE4DKCNK3
SCHEMBL6162568 0.90 LMNA (0.43) KCNK3KCNK5KCNA5KCNK17KCNK9
SCHEMBL6163159 0.89 POLB (0.47) PDE4APDE4BPDE4CPDE4DKCNK3
SCHEMBL6162446 0.89 KDM4E (0.43) KCNK3KCNK5KCNA5KCNK17KCNK9
SCHEMBL6161505 0.87 POLB (0.47) PDE4APDE4BPDE4CPDE4DPOLB
SCHEMBL6161355 0.85 HTT (0.40) PDE4APDE4BPDE4CPDE4DPOLB
SCHEMBL6162370 0.81 GABRP (0.46) MAPT
SCHEMBL6204124 0.79 POLB (0.53) POLB
SCHEMBL6160973 0.79 GABRP (0.46) MAPT
SCHEMBL6164599 0.77 ADORA2A (0.58) ADORA2AADORA1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1056724-B1 SUBSTITUTED CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORP (US) 2005-05-25 EP claimed
US-6448259-B1 CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR GAMMA AMINOBUTYRIC ACID BINDING SITE, THE BENZODIAZEPINE RECEPTOR; ANXIETY, SLEEP AND SEIZURE DISORDERS SEDATIVE, ANXIOLYTIC AND ANTICONVULSANT ACTIVITY NEUROGEN CORPORATION 2002-09-10 US claimed
EP-1056724-B1 SUBSTITUTED CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORP (US) 2005-05-25 EP disclosed
US-6448259-B1 CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR GAMMA AMINOBUTYRIC ACID BINDING SITE, THE BENZODIAZEPINE RECEPTOR; ANXIETY, SLEEP AND SEIZURE DISORDERS SEDATIVE, ANXIOLYTIC AND ANTICONVULSANT ACTIVITY NEUROGEN CORPORATION 2002-09-10 US disclosed
US-6194427-B1 BRAIN DISORDERS; PSYCHOLOGICAL DISORDERS; SLEEP DISORDERS; ANTICONVULSANTS NEUROGEN CORPORATION 2001-02-27 US disclosed
EP-1056724-A2 SUBSTITUTED CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 2000-12-06 EP disclosed
WO-1999043661-A2 SUBSTITUTED CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 1999-09-02 WO disclosed